Skip to content

Rhythm Pharmaceuticals

US · RYTM #1874 by market cap Listed 2017
112.36 -4.44 -3.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $159
    Market Newswire · 2026/10/8
  • Rating change
    Wolfe Research Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating
    Market Newswire · 2026/9/17
  • Rating change
    Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $150
    Market Newswire · 2026/8/25
  • Rating change
    J.P. Morgan Remains a Buy on Rhythm Pharmaceuticals (RYTM)
    TipRanks · 2026/9/16
  • Rating change
    Rhythm Pharmaceuticals (RYTM) Receives a Buy From H.C. Wainwright
    TipRanks · 2026/10/12
  • Rating change
    BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating
    Market Newswire · 2026/10/9
  • Citizens JMP Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $166
    Market Newswire · 2026/11/4
  • Rating change
    Deutsche Bank Initiates Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Announces Target Price $120
    Market Newswire · 2026/8/28
  • Rating change
    J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $145
    Market Newswire · 2026/10/15
  • Rating change
    A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $143 to $166
    Market Newswire · 2026/11/5
  • CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $168
    Market Newswire · 2026/11/5
  • Rating change
    Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143
    Market Newswire · 2026/10/20
  • Rating change
    H.C. Wainwright Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/10/12
  • Citi Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143
    Market Newswire · 2026/11/6
  • Rating change
    BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $150
    Market Newswire · 2026/11/4
  • Rating change
    J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating
    Market Newswire · 2026/9/16
  • Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $147
    Market Newswire · 2026/11/5
  • Rating change
    RBC Capital Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $155
    Market Newswire · 2026/9/15
  • J.P. Morgan Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Cuts Target Price to $142
    Market Newswire · 2026/11/6
  • Rating change
    William Blair Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $206
    Market Newswire · 2026/10/16
  • Rating change
    A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $130 to $160
    Market Newswire · 2026/8/5
  • Rating change
    Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $150
    Market Newswire · 2026/8/5
  • Rating change
    CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $151
    Market Newswire · 2026/7/8
  • Citi Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143
    Market Newswire · 2026/10/28
  • Rating change
    CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $154
    Market Newswire · 2026/8/5

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Rhythm Pharmaceuticals discussion 0 comments

Add a comment